Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report

Psoriasis is a recurring systemic disease that can be treated with biologics to some effect. However, precisely targeting inflammatory mediators may disrupt immune system homeostasis and lead to new conditions. Here, we report a case of psoriasiform dermatitis (PsoD) caused by IL-17 inhibitors (IL-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Nan, Zhong, Lingyuan, Luo, Nana, Wang, Qiuyue, Li, Tianhao, Hao, Pingsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204759/
https://www.ncbi.nlm.nih.gov/pubmed/37228572
http://dx.doi.org/10.2147/JIR.S412418
_version_ 1785045899679891456
author Luo, Nan
Zhong, Lingyuan
Luo, Nana
Wang, Qiuyue
Li, Tianhao
Hao, Pingsheng
author_facet Luo, Nan
Zhong, Lingyuan
Luo, Nana
Wang, Qiuyue
Li, Tianhao
Hao, Pingsheng
author_sort Luo, Nan
collection PubMed
description Psoriasis is a recurring systemic disease that can be treated with biologics to some effect. However, precisely targeting inflammatory mediators may disrupt immune system homeostasis and lead to new conditions. Here, we report a case of psoriasiform dermatitis (PsoD) caused by IL-17 inhibitors (IL-17i) namely secukinumab treatment for psoriasis. This case proposes an effective use of Janus kinase inhibitor (JAKi) tofacitinib to confront lesions induced by IL-17i. This is the first case report of PsoD caused by secukinumab treated with tofacitinib.
format Online
Article
Text
id pubmed-10204759
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-102047592023-05-24 Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report Luo, Nan Zhong, Lingyuan Luo, Nana Wang, Qiuyue Li, Tianhao Hao, Pingsheng J Inflamm Res Case Report Psoriasis is a recurring systemic disease that can be treated with biologics to some effect. However, precisely targeting inflammatory mediators may disrupt immune system homeostasis and lead to new conditions. Here, we report a case of psoriasiform dermatitis (PsoD) caused by IL-17 inhibitors (IL-17i) namely secukinumab treatment for psoriasis. This case proposes an effective use of Janus kinase inhibitor (JAKi) tofacitinib to confront lesions induced by IL-17i. This is the first case report of PsoD caused by secukinumab treated with tofacitinib. Dove 2023-05-19 /pmc/articles/PMC10204759/ /pubmed/37228572 http://dx.doi.org/10.2147/JIR.S412418 Text en © 2023 Luo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Luo, Nan
Zhong, Lingyuan
Luo, Nana
Wang, Qiuyue
Li, Tianhao
Hao, Pingsheng
Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
title Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
title_full Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
title_fullStr Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
title_full_unstemmed Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
title_short Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
title_sort tofacitinib for the treatment of psoriasiform dermatitis caused by il-17 inhibitors: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204759/
https://www.ncbi.nlm.nih.gov/pubmed/37228572
http://dx.doi.org/10.2147/JIR.S412418
work_keys_str_mv AT luonan tofacitinibforthetreatmentofpsoriasiformdermatitiscausedbyil17inhibitorsacasereport
AT zhonglingyuan tofacitinibforthetreatmentofpsoriasiformdermatitiscausedbyil17inhibitorsacasereport
AT luonana tofacitinibforthetreatmentofpsoriasiformdermatitiscausedbyil17inhibitorsacasereport
AT wangqiuyue tofacitinibforthetreatmentofpsoriasiformdermatitiscausedbyil17inhibitorsacasereport
AT litianhao tofacitinibforthetreatmentofpsoriasiformdermatitiscausedbyil17inhibitorsacasereport
AT haopingsheng tofacitinibforthetreatmentofpsoriasiformdermatitiscausedbyil17inhibitorsacasereport

Ejemplares similares